Hypofractionated radiation therapy, which is delivered in larger doses over a shorter time period than conventional RT, can result in similar rates of cure and side effects compared to a longer treatment schedule for some men with low-risk prostate cancer, according to research presented at the American Society for Radiation Oncology’s annual meeting.
Thomas J. Lynch Jr. and Howard A. “Skip” Burris III lead two institutions that couldn’t be more different—an NCI-designated Comprehensive Cancer Center on one side of the country and a for-profit research enterprise on the other—but they stay up at nights worrying about the same thing.
